Honing market access tactics given German drug assessment/price trends
This article was originally published in Scrip
Four years after its introduction, Germany's early benefit assessment process continues to make waves in the industry.
You may also be interested in...
Under forthcoming changes to the law, companies could gain confidential pricing in Germany, which could make it easier to defend a higher price in other countries. But sponsor of some orphan products may face a rockier path to market.
Including the impact on hospitalizations in the label for Novartis's heart failure drug Entresto was critical to enable execution of outcome-based agreements. Such deals present an opportunity for pharma and payers to work together, but many challenges remain.
Despite the challenges with the implementation of managed entry agreements, the debate involving these complex market access routes is not abating. Speakers at the International Society for Pharmacoeconomics and Outcomes Research Europe meeting in Milan on 7–11 November 2015 discussed current experiences with such agreements across Europe, as they are about to make a bigger showing across the Atlantic.